AUROBINDO PHARMA LTD vs MAX HEALTHCARE INS LTD

A side-by-side comparison of AUROBINDO PHARMA LTD (AUROPHARMA) and MAX HEALTHCARE INS LTD (MAXHEALTH) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, AUROBINDO PHARMA LTD leads AUROPHARMA vs MAXHEALTH on 9 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation40
  • Profitability04
  • Growth11
  • Size & financial health40
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

AUROPHARMA takes 4/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

27.91
P/E ratio
59.66
2.53
P/B ratio
9.41
0.24%
Dividend yield
0.19%
₹60.34
EPS
₹14.83

Profitability

MAXHEALTH takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

9.25%
Return on equity
13.42%
11.96%
Return on capital
13.43%
20.34%
EBITDA margin
26.79%
10.41%
Net margin
17.23%

Growth

Even

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.63%
Revenue CAGR (3Y)
22.43%
22.03%
Profit CAGR (3Y)
9.34%

Size & financial health

AUROPHARMA takes 4/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹96,882 Cr
Market cap
₹86,114 Cr
₹33,653 Cr
Revenue
₹8,373 Cr
₹3,503 Cr
Net profit
₹1,442 Cr
0.21
Debt / equity
0.32
AUROBINDO PHARMA LTD
  • + []
  • − ["The company has delivered a poor sales growth of 6.3% over past five years.", "The company has delivered a poor profit growth of -8.1% over past five years."]
MAX HEALTHCARE INS LTD
  • + ["Company has delivered good sales growth of 27.3% CAGR over last 5 years"]
  • − ["Stock is trading at 8.01 times its book value"]
AUROBINDO PHARMA LTD full analysis MAX HEALTHCARE INS LTD full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.